Literature DB >> 7799008

Chemotherapy in acute myelogenous leukemia: high dose, higher expectations?

E Berman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7799008     DOI： 10.1200/JCO.1995.13.1.1

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia.

Authors:  M Beksaç; O Arslan; H Koç; H Akan; O Ilhan; M Arat; M Ozcan; G Gürman; N Konuk; A Uysal
Journal:  Med Oncol       Date:  1998-09       Impact factor: 3.064

2.  Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.

Authors:  T Yamauchi; Y Kawai; N Goto; S Kishi; S Imamura; A Yoshida; Y Urasaki; T Fukushima; H Iwasaki; H Tsutani; M Masada; T Ueda
Journal:  Jpn J Cancer Res       Date:  2001-09

3.  Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional doses.

Authors:  T Yamauchi; Y Kawai; S Kishi; N Goto; Y Urasaki; S Imamura; T Fukushima; A Yoshida; H Iwasaki; H Tsutani; M Masada; T Ueda
Journal:  Jpn J Cancer Res       Date:  2001-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.